Recent advance in anti-fingolimod glioblastomas
10.3760/cma.j.issn.1671-8925.2017.01.022
- VernacularTitle:芬戈莫德抗胶质母细胞瘤的研究进展
- Author:
Pengliang CHEN
1
;
Rongcai JIANG
;
Zhong WANG
;
Ning SU
Author Information
1. 内蒙古医科大学研究生学院
- Keywords:
Glioblastoma;
Fingolimod;
Mechanism
- From:
Chinese Journal of Neuromedicine
2017;16(1):100-103
- CountryChina
- Language:Chinese
-
Abstract:
Fingolimod (FTY720) as a new immunosuppressive agent,is the prodrug of an sphingosine-1-phosphate receptor agonist.It is a potent immunosuppressant which has been approved by the US Food and Drug Administration to treat relapsing-remitting multiple sclerosis,and shows its unique and novel mechanism of action.Unlike the traditional immunosuppressive agents,fingolimod exerts immunosuppressive and immunoregulatory functions mainly through interaction with shhingosine-l-phosphate receptors on the cell surface without affecting activation and proliferation of lymphocytes.In addition,FTY720 has been shown to inhibit a variety of cancer related signal transduction pathways.It also presented significant anticancer effects in the in vivo and in vitro experiments.And in the treatment of glioblastoma multiforme (GBM) experiment,FTY720 displayed excellent activity as well had a synergistic effect in addition to temozolomid,the current standard chemotherapeutic agent to treat malignant gliomas.This article reviewed the advances in study on the anti-GBM effect and mechanism of FTY720.
